ArticleClinical and translational medicine2026
Cascade-targeted intervention of the NLRP3 inflammasome and downstream angiogenesis by curcumin nanoparticles for ocular neovascularization therapy.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRetinal neovascularization (RNV) causes irreversible vision loss. Despite the benefits of anti-VEGF therapy, incomplete responses and persistent inflammation necessitate complementary treatments. Curcumin has anti-inflammatory and anti-angiogenic activity, but its poor solubility and bioavailability limit ocular application.
methodsPLGA-encapsulated curcumin nanoparticles (Cur-NPs; approximately 125 nm) were produced using an ultrasound-microreactor platform. Therapeutic efficacy was assessed in oxygen-induced retinopathy (OIR) and Rho/VEGF transgenic mouse models following intravitreal administration. Neovascularization, vascular leakage, retinal structure, apoptosis, retinal distribution, and intraocular retention were evaluated using histology, fluorescence imaging, and longitudinal in vivo imaging. Mechanisms were investigated using single-cell transcriptomics, untargeted metabolomics, genetic loss-of-function, and pharmacological perturbation. Conbercept monotherapy and Cur-NP combination treatment were also evaluated.
resultsCur-NPs reduced pathological neovascularization in both models and improved vascular integrity, decreased vascular leakage, preserved retinal architecture, and attenuated apoptosis in OIR mice. Compared with free curcumin, Cur-NPs showed broader retinal fluorescence distribution and prolonged intraocular fluorescence retention. Cur-NPs suppressed the NLRP3ASCCaspase-1 inflammasome and associated VEGF/VEGFR2 signaling. Genetic and pharmacological experiments supported a functional contribution of NLRP3 signaling to the anti-angiogenic effects of Cur-NPs. Multi-omics analyses revealed treatment-associated changes in retinal immune-cell states and metabolic pathways. ConberceptCur-NP combination therapy reduced neovascularization more than either treatment alone.
conclusionsCur-NPs inhibit pathological RNV through modulation of NLRP3-associated inflammatoryangiogenic signaling while improving retinal protection and intraocular retention. These findings support further evaluation of Cur-NPs as a potential upstream anti-inflammatory adjunct to VEGF-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.